Skip to content

Experimentation With Screening for Bronchopulmonary Cancer and Primary Cardiovascular Prevention, Early Management of COPD and an Offer Exempted From Smoking Cessation

Bronchopulmonary Cancer Screening Program and Primary Cardiovascular Prevention, Early Management of COPD and Smoking Cessation

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05440123
Acronym
LUMASCAN-2
Enrollment
300
Registered
2022-06-30
Start date
2025-12-01
Completion date
2032-11-30
Last updated
2025-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

the Rate of Participation in Screening for PBC

Brief summary

The study consists of recruiting a target population by sending a letter from the Regional Center for Cancer Screening in Ile de France. In the screening program, a battery of examinations will be carried out at inclusion, one year, 2 years, 3 years, 4 years and 5 years.

Detailed description

The patients will be recruited by correspondence by by sending a letter from the Regional Center for Cancer Screening in Ile de France. When the patient has agreed to participate, a screening program will be carried out The screening program includes performing a low-dose chest CT scan (STBD), spirometry, blood sampling (biobank + screening for cardiovascular risk factors) on inclusion, at 1 year and at 2 years. Subsequently, a telephone interview will be scheduled for 3 years to collect medical information, for a total follow-up period of 5 years. At each visit, a structured offer of smoking cessation will be proposed and a collection of the quality of life will be carried out. Each year, a telephone call from participants will be scheduled in order to maximize participation

Interventions

OTHERscreening for bronchopulmonary cancer

The screening program includes performing a low-dose chest CT scan (STBD), spirometry, blood sampling (biobank + screening for cardiovascular risk factors) on inclusion, at 1 year and at 2 years. Subsequently, a telephone interview will be scheduled for 3 years to collect medical information, for a total follow-up period of 5 years. At each visit, a structured offer of smoking cessation will be proposed and a collection of the quality of life will be carried out. Each year, a telephone call from participants will be scheduled in order to maximize participation

Sponsors

Centre Hospitalier Intercommunal Creteil
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
55 Years to 74 Years

Inclusion criteria

* Women and men * Age: 55 to 74 years old * Smokers at more than 20 pack-years weaned for less than 15 years * Affiliated to a social security organization

Exclusion criteria

* Presence of signs of PBC * Subjects with a personal history of PBC of less than 5 years or under treatment * Presence of serious comorbidities involving the vital prognosis at 6 months * Subjects who have already benefited from a chest CT scan less than one year old. * Refusal to participate in the study * Absence of exposure to tobacco or insufficient exposure to tobacco or withdrawal \> 15 years * Patient on long-term oxygen therapy * Metal implants (thorax, spine) which can cause a deterioration in the quality of the image of the low dose scanner * Subject included in another study protocol

Design outcomes

Primary

MeasureTime frame
Rate of population participation in PBC screeningBaseline

Contacts

Primary ContactSébastien Gendarme, MD
sebastien.gendarme@chicreteil.fr01.57.02.20.90
Backup ContactCamille JUNG
camille.jung@chicreteil.fr0145175000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026